Ankylosing spondylitis
From the Journals
Psoriatic arthritis and axial spondyloarthritis patients succeed with reduced TNF inhibitor dosing
Patients in a stable low–disease activity state who reduced their TNF inhibitor dose over time based on disease activity showed no increase in...
From the Journals
Better COVID-19 outcomes confirmed in TNF inhibitor users
A study of three international registries confirms that patients with immune-mediated inflammatory diseases who are taking a TNF inhibitor should...
From the Journals
Tramadol linked to higher risk of mortality, compared with codeine
Tramadol is widely used for noncancer pain but, as compared with codeine, it was associated with a higher risk for adverse outcomes, including...
From the Journals
U.S. arthritis prevalence continues steady rise; activity limitations grow more rapidly
The latest survey data indicated that more Americans have arthritis than ever before, possibly because of an aging population, worsening...
News from the FDA/CDC
Adalimumab biosimilar Cyltezo gets interchangeability designation
The approval of the supplemental biologics license application for Cyltezo makes the adalimumab biosimilar just the second biosimilar to be...
Latest News
Upadacitinib meets primary endpoints for improvement in ankylosing spondylitis and nonradiographic disease
Top-line results released by AbbVie show significant reductions in signs and symptoms, with a favorable safety profile.
Feature
Acceptance of biosimilars grows but greater use may hinge on switching, interchangeability studies
The slow adoption of biosimilars in the United States has begun to pick up and experts hope that they can put a brake on drug spending, but...
Conference Coverage
Early vs. late TNFi switch in AS patients associated with different risk factors
Different factors were associated with switching an initial TNF inhibitor within 2 years versus after 2 years of treatment.
Conference Coverage
Real-world data generate debate on definition of flare in axial spondyloarthritis
Changes in the Bath Ankylosing Spondyloarthritis Disease Activity Index could be used to monitor patient-reported flares in axial...
Conference Coverage
Targeting IL-23 could still be important for axial spondyloarthritis treatment
Results of a systematic review and meta-analysis corroborate negative trial findings for IL-23 but hint at some early benefit with risankizumab....
Latest News
European agency recommends two new adalimumab biosimilars
The Committee for Medicinal Products for Human Use gave a positive opinion for the approval of Hukyndra and Libmyris, each of which will have 15...